Physician profile
Abdul Keylani
NPI 1386692689
$17,252.19
in general payments reported to CMS, 2019-2025
45 companies · $2,006 in 2025
The $2,006 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,801 · 2020: $636 · 2021: $3,048 · 2022: $3,801 · 2023: $1,463 · 2024: $2,497 · 2025: $2,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,761 · Travel and Lodging: $195 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,760.80 |
| Travel and Lodging | $194.90 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,223.35 | 2021-2025 | Onyx Frontier, Corevalve Evolut R, Symplicity G3 |
| Abiomed | $1,881.37 | 2019-2025 | Impella |
| Penumbra, INC. | $1,388.56 | 2019-2024 | Indigo System |
| Medtronic Vascular, INC. | $1,150.17 | 2019-2020 | |
| Abbott Laboratories | $1,077.90 | 2019-2025 | Aveir, Cardiomems, Ensite |
| Novartis Pharmaceuticals Corporation | $890.36 | 2019-2025 | |
| Biotronik INC. | $834.43 | 2019-2025 | Orsiro Mission, Pantera Leo, Recross |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $678.48 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $647.45 | 2021-2025 | Verquvo, Belsomra |
| Boston Scientific Corporation | $440.72 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $418.42 | 2019-2024 | Farxiga |
| Pfizer INC. | $330.15 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $328.73 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $285.49 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $246.86 | 2020-2025 | Eliquis, Camzyos |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $233.34 | 2021-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.74 | 2019-2021 | |
| Amgen INC. | $186.81 | 2019-2025 | Repatha, Repatha |
| Inari Medical, INC. | $173.18 | 2022 | |
| Biosense Webster, INC. | $146.12 | 2025 | Carto 3 |
| Teleflex LLC | $140.00 | 2025 | Guideliner |
| Alnylam Pharmaceuticals INC. | $129.84 | 2023-2024 | Onpattro |
| Shockwave Medical, INC | $116.11 | 2025 | |
| Zoll Respicardia, INC. | $107.43 | 2023 | Remede System |
| Philips North America LLC | $104.30 | 2022 | |
| Lilly USA, LLC | $96.19 | 2024 | Mounjaro |
| Lantheus Medical Imaging, INC. | $94.70 | 2020 | |
| Impulse Dynamics (USA) INC. | $94.41 | 2021 | |
| Atricure, INC. | $93.32 | 2023-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Cardiovascular Systems INC. | $78.35 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $75.19 | 2021-2023 | Arcalyst |
| Vifor Pharma, INC. | $47.24 | 2020-2021 | |
| Stryker Corporation | $44.88 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Acist Medical Systems, INC. | $38.30 | 2020-2022 | |
| Tactile Systems Technology INC | $27.67 | 2021-2024 | Flexitouch Plus, Entre Plus |
| Reflow Medical INC | $27.28 | 2025 | |
| Angiodynamics, INC. | $26.84 | 2022 | |
| Nevro Corp. | $21.17 | 2024 | Senza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.99 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $15.29 | 2024 | Arcalyst |
| Chiesi USA, INC. | $15.21 | 2019 | |
| Heartflow, INC. | $14.30 | 2024 | |
| Getinge USA Sales, LLC | $12.95 | 2019 | |
| Edwards Lifesciences Corporation | $12.73 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Keylani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.